<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669890</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA2533</org_study_id>
    <secondary_id>CHNY-01-515</secondary_id>
    <nct_id>NCT00669890</nct_id>
  </id_info>
  <brief_title>Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML</brief_title>
  <acronym>High Risk</acronym>
  <official_title>Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide
      followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well
      tolerated.

      This study will attempt to determine the maximum tolerated dose of the immune therapy
      (gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this
      study for allogeneic stem cell transplant. (Part A)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemtuzumab Ozogamicin (CMA-676) is a chemotherapeutic agent consisting of recombinant
      humanized anti-CD33 antibody conjugated with calicheamicin, a highly potent cytotoxic
      antitumor antibiotic. The antibody portion of Gemtuzumab binds specifically to the CD33
      antigen, a sialic acid-dependent adhesion protein expressed on the surface of leukemia
      blasts, normal and leukemic myeloid colony-forming cells, including leukemic clonogenic
      precursors, but excluding pluripotent hematopoietic stem cells and nonhematopoietic cells.
      This results in formation of the complex that is internalized, upon which calicheamicin
      derivative is released with in the lysosomes of the myeloid cell. The free calicheamicin
      derivative then binds to the DNA, resulting in DNA double strand breaks and consequential
      cell death.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose or tolerable dose of Gemtuzumab Ozogamicin (anti-CD33 immunotoxin) therapy combined with Busulfan/ Cyclophosphamide in the conditioning regimen prior to AlloSCT in patients with high risk CD33+ AML/JMML/MDS</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes, if applicable, of minimal residual disease (cytogenetics, FISH, RT-PCR) in patients with high risk CD33+ AML/JMML/MDS after AlloSCT.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS), overall survival (OS), and disease free survival (DFS), (if applicable), following GO, Bu/CY and AlloSCT in patients with high risk CD33+ AML/JMML/MDS.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before and after GO, Bu/CY conditioning and AlloSCT in patients with high risk CD33+ AML/JMML/MDS</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>study 515</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Dose Escalation</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>Gemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Conditioning Regimen</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Conditioning Regimen</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>(Unrelated Donors only)</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>GVHD Prophylaxis</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>GVHD Prophylaxis</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>GVHD Prophylaxis</description>
    <arm_group_label>study 515</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility

        Inclusion Criteria:

        Disease Status

          -  AML Induction Failure

          -  AML in 1st, 2nd, or 3rd Relapse (&gt;10% bone marrow blasts)

          -  AML greater than or equal to 3rd CR

          -  MDS with &gt;6% bone marrow blasts at diagnosis

          -  Secondary MDS with less than or equal to 5% bone marrow myeloblasts at diagnosis

          -  JMML with &gt;6% bone marrow myeloblasts at diagnosis

        Disease Immunophenotype Patients (AML only) receiving gemtuzumab ozogamicin must express
        minimum of &gt;10% or =10% CD33 positivity. Patients with &lt;10% CD33 positivity will not
        receive gemtuzumab ozogamicin.

        Organ Function

        Patients must have adequate organ function as defined below:

          -  Adequate renal function defined as:

          -  Serum creatinine &lt;1.5 x normal, or

          -  Creatinine clearance or radioisotope GFR 40 ml/min/m2 or &gt;60 ml/min/1.73 m2 or an
             equivalent GFR as determined by the institutional normal range

          -  Adequate liver function defined as:

          -  Total bilirubin 1.5 x normal, or SGOT (AST) or SGPT (ALT) &lt;2.0 x normal or =2.0 x
             normal

          -  Adequate cardiac function defined as:

          -  Shortening fraction of &gt;27% by echocardiogram, or

          -  Ejection fraction of &gt;47% by radionuclide angiogram or echocardiogram

          -  Adequate pulmonary function defined as:

          -  DLCO &gt;55% or =55% by PFT

          -  For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air

        Exclusion Criteria:

          -  Patients with active CNS AML/JMML/MDS disease at time of conditioning therapy

          -  Female patients who are pregnant (positive HCG)

          -  Karnofsky &lt;50% or Lansky &lt;50% if 10 years or less

          -  Age &gt;65 years

          -  Has received gemtuzumab in the previous 30 days or has not recovered from prior
             gemtuzumab therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of NYP</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrensnyp.org</url>
    <description>(Click on &quot;Morgan Stanley Children's Hospital&quot; and then &quot;Clinical Services&quot; and then &quot;Blood &amp; Marrow Transplantation&quot;)</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>JMML</keyword>
  <keyword>MDS</keyword>
  <keyword>Allogenic Atem Cell Transplant</keyword>
  <keyword>Gemtuzumab Ozogamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

